Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
8 U# Q+ _- h: N4 qNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 4 H' `5 }: @9 a; Q( [& H
+ Author Affiliations: n4 g( i1 X9 O6 Y ]. _/ }: u
4 L8 n) h5 @* M ~3 _9 w1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
) ?1 i, o V4 c' i7 J; G& o$ y2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
5 W$ T+ V7 s" y3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
( F# |& U$ J$ D: Q4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 9 j7 u8 i8 T6 e" G
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan , `- E" H3 o% i( x5 o$ R
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
% ~9 V6 T! ^: ?! Z: Z7Kinki University School of Medicine, Osaka 589-8511, Japan
, m8 S3 t, t5 o, e+ _8Izumi Municipal Hospital, Osaka 594-0071, Japan . K ], [. i$ W" L* G
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
: @: {% {8 M9 _5 I& {0 u1 k% aCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
4 m; }% [% l4 gAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
8 s: q7 Y! [& ~ h
' l* U6 M5 ]$ E: P1 R |